Overview
Clinical Meaning
Benzodiazepines carry significant risks that the NP must weigh against therapeutic benefits.
Benzodiazepines carry significant risks that the NP must weigh against therapeutic benefits. Physiological dependence develops through GABA-A receptor adaptation: chronic benzodiazepine exposure causes downregulation and conformational changes in GABA-A receptors (decreased receptor density and reduced sensitivity), while simultaneously upregulating excitatory glutamate (NMDA) receptor activity as a compensatory mechanism. When the benzodiazepine is abruptly discontinued, the brain is left in a state of reduced GABAergic inhibition and enhanced glutamatergic excitation, producing withdrawal syndrome. Benzodiazepine withdrawal ranges from mild (anxiety rebound, insomnia, tremor) to life-threatening (seizures, delirium tremens-like syndrome, psychosis). Withdrawal severity depends on duration of use, dose, half-life of the agent (short-acting agents like alprazolam produce more severe withdrawal), and patient factors (elderly, hepatic impairment). The withdrawal timeline is predictable: short-acting agents (alprazolam, lorazepam) produce withdrawal within 24-48 hours of last dose; long-acting agents (diazepam, chlordiazepoxide) produce withdrawal at 3-7 days. The NP must understand tolerance development: pharmacodynamic tolerance (receptor downregulation) occurs to sedative and anxiolytic effects within 2-4 weeks, leading to dose escalation. Cross-tolerance exists with alcohol and barbiturates because all three act on the GABA-A receptor complex. This cross-tolerance...